On January 30, 2026, Pacific Biosciences of California, Inc. completed an asset sale, receiving $50 million in cash and assuming certain liabilities, related to its short-read DNA sequencing technology. This event is significant for the company from an equity investor perspective and is categorized under 'Disposals and divestitures.'